529 related articles for article (PubMed ID: 26659069)
1. Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.
Klassen KM; Kimlin MG; Fairley CK; Emery S; Anderson PH; Ebeling PR;
Osteoporos Int; 2016 May; 27(5):1737-45. PubMed ID: 26659069
[TBL] [Abstract][Full Text] [Related]
2. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Tebas P; Myers L; Melbourne K; Ha B; Sax PE
J Infect Dis; 2011 Jun; 203(12):1791-801. PubMed ID: 21606537
[TBL] [Abstract][Full Text] [Related]
3. Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults.
Grant PM; Kitch D; McComsey GA; Tierney C; Ha B; Brown TT
HIV Clin Trials; 2015; 16(2):66-71. PubMed ID: 25872972
[TBL] [Abstract][Full Text] [Related]
4. Bone Density, Microarchitecture, and Tissue Quality After Long-Term Treatment With Tenofovir/Emtricitabine or Abacavir/Lamivudine.
Güerri-Fernández R; Molina-Morant D; Villar-García J; Herrera S; González-Mena A; Guelar A; Trenchs-Rodríguez M; Díez-Pérez A; Knobel H
J Acquir Immune Defic Syndr; 2017 Jul; 75(3):322-327. PubMed ID: 28418990
[TBL] [Abstract][Full Text] [Related]
5. Impact of switching from zidovudine to tenofovir disoproxil fumarate on bone mineral density and markers of bone metabolism in virologically suppressed HIV-1 infected patients; a substudy of the PREPARE study.
Cotter AG; Vrouenraets SM; Brady JJ; Wit FW; Fux CA; Furrer H; Brinkman K; Sabin CA; Reiss P; Mallon PW;
J Clin Endocrinol Metab; 2013 Apr; 98(4):1659-66. PubMed ID: 23436922
[TBL] [Abstract][Full Text] [Related]
6. Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
Curran A; Martinez E; Podzamczer D; Lonca M; Barragan P; Crespo M; Falco V; Vidal-Sicart S; Imaz A; Martinez M; Gatell JM; Ribera E
Antivir Ther; 2012; 17(4):711-8. PubMed ID: 22374987
[TBL] [Abstract][Full Text] [Related]
7. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Haskelberg H; Hoy JF; Amin J; Ebeling PR; Emery S; Carr A; STEAL Study Group
PLoS One; 2012; 7(6):e38377. PubMed ID: 22719882
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women With HIV: Laboratory and Clinical Outcomes in an Observational National Study.
Floridia M; Pinnetti C; Ravizza M; Masuelli G; Personeni C; Sansone M; Degli Antoni A; Guaraldi G; Spinillo A; Tassis B; Dalzero S; Liuzzi G; Tamburrini E
J Acquir Immune Defic Syndr; 2018 May; 78(1):99-104. PubMed ID: 29406430
[TBL] [Abstract][Full Text] [Related]
9. Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.
Rasmussen TA; Jensen D; Tolstrup M; Nielsen US; Erlandsen EJ; Birn H; Østergaard L; Langdahl BL; Laursen AL
PLoS One; 2012; 7(3):e32445. PubMed ID: 22479327
[TBL] [Abstract][Full Text] [Related]
10. HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Haskelberg H; Cordery DV; Amin J; Kelleher AD; Cooper DA; Emery S;
PLoS One; 2014; 9(3):e93333. PubMed ID: 24681993
[TBL] [Abstract][Full Text] [Related]
11. Bone Mineral Density and Vitamin D Levels in HIV Treatment-Naïve African American Individuals Randomized to Receive HIV Drug Regimens.
Cook PP; Stang AT; Walker LR; Akula SM; Cook FJ
South Med J; 2016 Nov; 109(11):712-717. PubMed ID: 27812717
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
Campbell L; Ibrahim F; Barbini B; Samarawickrama A; Orkin C; Fox J; Waters L; Gilleece Y; Tariq S; Post FA;
HIV Med; 2022 Apr; 23(4):362-370. PubMed ID: 34866304
[TBL] [Abstract][Full Text] [Related]
13. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
[TBL] [Abstract][Full Text] [Related]
14. Tenofovir disoproxil fumarate appears to disrupt the relationship of vitamin D and parathyroid hormone.
Havens PL; Long D; Schuster GU; Gordon CM; Price G; Wilson CM; Kapogiannis BG; Mulligan K; Stephensen CB;
Antivir Ther; 2018; 23(7):623-628. PubMed ID: 30260797
[TBL] [Abstract][Full Text] [Related]
15. Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
Mulligan K; Glidden DV; Anderson PL; Liu A; McMahan V; Gonzales P; Ramirez-Cardich ME; Namwongprom S; Chodacki P; de Mendonca LM; Wang F; Lama JR; Chariyalertsak S; Guanira JV; Buchbinder S; Bekker LG; Schechter M; Veloso VG; Grant RM;
Clin Infect Dis; 2015 Aug; 61(4):572-80. PubMed ID: 25908682
[TBL] [Abstract][Full Text] [Related]
16. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
Moyle GJ; Stellbrink HJ; Compston J; Orkin C; Arribas JR; Domingo P; Granier C; Pearce H; Sedani S; Gartland M;
Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468
[TBL] [Abstract][Full Text] [Related]
17. Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Haskelberg H; Pocock N; Amin J; Ebeling PR; Emery S; Carr A; ; Allworth A
PLoS One; 2014; 9(4):e94858. PubMed ID: 24722774
[TBL] [Abstract][Full Text] [Related]
18. Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial.
Boontanondha P; Nimitphong H; Musikarat S; Ragkho A; Kiertiburanakul S
Curr HIV Res; 2020; 18(1):52-62. PubMed ID: 31906840
[TBL] [Abstract][Full Text] [Related]
19. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
[TBL] [Abstract][Full Text] [Related]
20. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]